Reaction

Skin Toxicity reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 5,506 reports · 128 co-occurring drugs

As of the last recalculation, Skin Toxicity appears in 5,506 FAERS reports alongside 128 co-occurring drug terms. The strongest observed disproportionality signal is PANITUMUMAB (PRR 261.5).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Panitumumab	906	261.5	277.6
Vemurafenib	176	57.2	58.0
Cetuximab	359	46.3	46.8
Fluorouracil Cream, 0.5%	777	44.7	45.1
Fluorouracil	777	44.0	44.5
Oxaliplatin	694	40.3	40.7
Anti-Thymocyte Globulin (Rabbit)	66	31.3	31.5
Sorafenib	148	27.7	27.8
Erlotinib	69	27.3	27.4
Pemetrexed	143	25.9	26.0
Lapatinib	90	22.3	22.4
Erlotinib Hydrochloride	72	22.0	22.1
Trametinib	134	21.5	21.6
Pemetrexed Disodium	201	20.7	20.8
Irinotecan Hydrochloride	69	20.5	20.6
Thiotepa	51	20.4	20.5
Dabrafenib	109	19.9	20.0
Leucovorin Calcium	96	19.3	19.4
Regorafenib	57	18.7	18.8
Capecitabine	419	18.6	18.7
Gefitinib	42	17.7	17.8
Busulfan	67	16.3	16.3
Paclitaxel (Aibumin-Bound)	321	15.6	15.7
Fludarabine Phosphate	157	15.5	15.6
Carboplatin	469	15.2	15.2
Docetaxel Anhydrous	253	14.8	14.9
Docetaxel	253	14.8	14.9
Pembrolizumab	378	14.5	14.6
Paclitaxel	355	14.4	14.5
Alpelisib	32	14.0	14.0
Pertuzumab	97	13.7	13.8
Nevirapine	32	13.5	13.5
Atezolizumab	131	13.0	13.1
Ribociclib	106	12.9	13.0
Filgrastim	115	11.8	11.8
Fulvestrant	101	11.8	11.8
Cytarabine	180	11.7	11.7
Bendamustine Hcl	46	11.3	11.3
Ado-Trastuzumab Emtansine	24	10.8	10.8
Encorafenib	28	10.7	10.8
Trastuzumab	188	10.7	10.7
Bevacizumab	328	10.6	10.6
Imatinib	46	9.9	10.0
Gemcitabine	97	9.5	9.5
Osimertinib	78	9.3	9.3
Gemcitabine Hydrochloride	128	9.3	9.3
Exemestane	52	9.3	9.3
Ipilimumab	103	9.2	9.2
Etoposide	173	9.2	9.2
Apalutamide	28	9.0	9.1
Cabozantinib	112	9.0	9.0
Nivolumab	210	8.5	8.5
Letrozole Tablets	104	8.3	8.3
Durvalumab	44	8.2	8.2
Granisetron Hydrochloride	21	7.6	7.6
Letrozole	120	7.5	7.5
Cisplatin	150	7.4	7.4
Bleomycin Sulfate	20	7.3	7.4
Cyclophosphamide Injection, Solution	326	7.3	7.3
Cyclophosphamide	326	7.3	7.3
Cyclophosphamide For Injection	326	7.3	7.3
Granisetron	20	7.2	7.2
Everolimus Tablets	31	7.0	7.0
Doxorubicin	160	7.0	7.0
Trifluridine And Tipiracil	19	6.7	6.7
Sunitinib Malate	66	6.4	6.4
Minocycline	19	6.2	6.2
Melphalan Hydrochloride	39	5.9	5.9
Bosutinib	14	5.9	5.9
Zoledronic Acid	60	5.7	5.7
Abemaciclib	29	5.5	5.5
Melphalan	31	5.2	5.2
Bendamustine Hydrochloride	16	5.1	5.1
Doxorubicin Hydrochloride	43	5.0	5.0
Dasatinib	47	4.8	4.8
Mercaptopurine	22	4.8	4.8
Ifosfamide	27	4.8	4.8
Crizotinib	16	4.8	4.8
Nilotinib	36	4.6	4.6
Everolimus	61	4.6	4.6
Quinine	10	4.4	4.4
Daptomycin	10	4.1	4.1
Zidovudine	14	4.0	4.0
Ibrutinib	81	3.8	3.8
Fondaparinux Sodium	8	3.7	3.7
Axitinib	18	3.5	3.5
Voriconazole Injection	20	3.5	3.5
Aflibercept	28	3.4	3.4
Aprepitant	16	3.3	3.3
Cladribine	8	3.1	3.2
Temozolomide	17	3.1	3.1
Dexamethasone Sodium Phosphate	8	3.0	3.0
Carfilzomib	22	2.9	2.9
Pazopanib Hydrochloride	21	2.9	2.9
Piperacillin Sodium,Tazobactam Sodium	20	2.9	2.9
Dexamethasone 1.5 Mg	215	2.8	2.8
Dexamethasone	215	2.8	2.8
Fosaprepitant Dimeglumine	10	2.8	2.8
Mesna Injection	6	2.7	2.7
Amphotericin B	9	2.7	2.7
Mesna	6	2.7	2.7
Lamivudine Oral	18	2.7	2.7
Anastrozole Tablets	15	2.6	2.6
Voriconazole	21	2.6	2.6
Brentuximab Vedotin	7	2.6	2.6
Ondansetron	72	2.5	2.5
Ondansetron Tablets	72	2.5	2.5
Quinapril Hydrochloride	5	2.4	2.4
Ondansetron Hydrochloride	76	2.4	2.4
Ritonavir 100 Mg	9	2.3	2.3
Palbociclib	56	2.2	2.2
Loperamide Hydrochloride Oral	6	2.2	2.2
Lamivudine	18	2.2	2.2
Bortezomib	51	2.2	2.2
Lenvatinib	18	2.1	2.1
Efavirenz	6	2.0	2.0
Imatinib Mesylate	13	1.8	1.8
Azacitidine	12	1.5	1.5
Daratumumab	16	1.5	1.5
Olaparib	8	1.4	1.4
Abiraterone	5	1.4	1.4
Denosumab	71	1.3	1.3
Ixazomib	10	1.3	1.3
Azacitidine For	6	1.2	1.2
Lenalidomide	124	1.1	1.1
Pegfilgrastim	23	0.9	0.9
Pomalidomide	23	0.8	0.8
Pirfenidone	7	0.6	0.6

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.